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Abstract
Secretoneurin (SN) is a functional secretogranin II (SgII)-derived peptide that stimulates luteinizing
hormone (LH) production and its release in the goldfish. However, the effects of SN on the pituitary of
mammalian species and the underlying mechanisms remain poorly understood. To study SN in
mammals, we adopted the mouse LβT2 gonadotropin cell line that has characteristics consistent with
normal pituitary gonadotrophs. Using radioimmunoassay and real-time RT-PCR, we demonstrated that
static treatment with SN induced a significant increment of LH release and production in LβT2 cells in
vitro. We found that GnRH increased cellular SgII mRNA level and total SN-immunoreactive protein
release into the culture medium. We also report that SN activated the extracellular signal-regulated
kinases (ERK) in either 10-min acute stimulation or 3-h chronic treatment. The SN-induced ERK
activation was significantly blocked by pharmacological inhibition of MAPK kinase (MEK) with PD-
98059 and protein kinase C (PKC) with bisindolylmaleimide. SN also increased the total cyclic adenosine
monophosphate (cAMP) levels similarly to GnRH. However, SN did not activate the GnRH receptor.
These data indicate that SN activates the protein kinase A (PKA) and cAMP-induced ERK signaling
pathways in the LH-secreting mouse LβT2 pituitary cell line.
Keywords: secretogranin II, gonadotropin-releasing hormone
AS ONE OF THE MAJOR GRANIN PROTEINS, secretogranin II (SgII) was initially characterized in bovine anterior
pituitary (31). It is an ∼600-amino acid, very acidic, tyrosine-sulfated protein located in secretory
granules of vertebrate neuroendocrine cells (4, 8, 22, 26). Numerous small potentially bioactive peptides
are derived from SgII precursor processing, but only the 33- to 34-amino acid segment, termed
secretoneurin (SN), is conserved from fish to mammals (13, 48). In human pituitary, SgII
immunoreactivity (IR) is localized to gonadotrophs, thyrotrophs, and corticotrophs (39). SgII IR was
detected in the secretory granules and colocalized with LH in bovine gonadotroph, indicating the
copackaging of granins and gonadotropins to form secretory granules (3). Two types of secretory
granules were visualized in rat gonadotrophs: a large-sized moderately electron-dense granule and a
small-sized electron-dense granule. The latter granule contained exclusively the immunoreactive signals
of SgII and LH (41). In addition to the pituitaries of cow, rat and mouse, SgII was found in the LH-
positive granules from female sheep gonadotrophs (6). The above immunocytochemical studies and
other work on in vivo LH release (7) reveal an important association of SgII-related products and LH in
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Neuropeptides.
Culture and static incubation of LβT2 gonadotrophs.
RIA.
RNA isolation, cDNA preparation, and real-time RT-PCR analysis.
mammalian gonadotrophs.
Nicol et al. (28) utilized radioimmunoassay (RIA) to investigate protein release from the mouse LβT2
gonadotroph cell line. They observed that pulsatile GnRH treatments resulted in the marked increments
of both LH and SgII release together at each time point, suggesting a close correlation between the
secretions of these two proteins. Nicol et al. (29) also demonstrated that LH, but not follicle-stimulating
hormone (FSH), is coreleased with SgII and chromogranin A (CgA) in response to GnRH in LβT2 cells,
indicating that GnRH-stimulated LH secretion is via the regulated granin-associated pathway.
Our previous studies in the goldfish model revealed that SN not only stimulates the secretion and
production of LH in vivo (4) and in vitro (45, 47, 50) but is also generated from proteolytic processing of
SgII in the brain and pituitary (46, 47). Therefore, both neuroendocrine and paracrine sources of SN are
involved in stimulation of gonadotroph function in the goldfish pituitary (50). We hypothesize that the
well-conserved SN peptide also plays a role in regulating LH secretion in mammals. The mouse LβT2
gonadotroph cell line was chosen because it is a highly amenable model system that exhibits the major
functional characteristics consistent with those of normal mammalian pituitary gonadotrophs (38) and
produces SgII (28, 29), and intracellular signal transduction pathways are well described (14, 19, 20, 32,
40, 43). Our results show that SN simulates intracellular signaling pathways similar to those regulated
by GnRH. Given that mouse LβT2 cells also release SN-immunoreactive peptides, SN may be part of an
paracrine and/or autocrine mechanism regulating LH release.
MATERIALS AND METHODS
The mammalian GnRH agonist [mGnRH-A (Des-Gly , D-Leu , Pro-NHEt )-LHRH]
was purchased from Bachem Bioscience (King of Prussia, PA). The 33-amino acid mouse SN (mSN)
peptide was synthesized on Fmoc-PAL-PEG polystyrene solid support by using an automated peptide
synthesizer (Pioneer; PE-PerSeptive Biosystems, Framingham, MA) following HATU/DIEA-mediated
Fmoc chemistry and purified by reversed-phase HPLC (2).
The LβT2 gonadotroph cell line was generously
provided by Dr. P. Mellon (University of California, San Diego, CA). The culture method was described
previously (38). Prior to each static incubation experiment, the cells were plated in 24-well culture plates
at a density of ∼2.5 × 10  cells/well or six-well culture plates at a density of ∼2.0 × 10  cells/well and
cultured in the 5% CO  air at 37°C for 48 h. At the beginning of experimentation, the medium was
replaced with DMEM containing either 10 nM mGnRH-A or various doses of SN (1–100 nM). After the
individual static treatments of 3, 6, and/or 12 h, depending on the experiment, media were collected and
stored at −20°C for radioimmunoassay of LH. Moreover, cells were removed from the plate bottom and
kept at −80°C for RNA or protein extraction. For the study of the signaling pathway, cells were starved in
serum-free DMEM overnight in a wet 5% CO  atmosphere at 37°C at first before the static treatment of
mGnRH-A (100 nM) and SN (10 and/or 100 nM) for 10 min or 3 h. For blocking the PKC-MAPK
pathway, 20 μM PD-98059 (a MEK inhibitor; Cell Signaling Technology, Danvers, MA) and 2 μM
bisindolylmaleimide I (BIM-1, a PKC inhibitor; Calbiochem, La Jolla, CA) were utilized to pretreat the
LβT2 cells for 1 and 0.5 h, respectively, prior to the 10-min acute stimulation of mGnRH-A (100 nM)
and SN (100 nM). PD-98059 and BIM-1 were chosen because they were shown to be effective in other
experiments with LβT2 cells (19).
The LH levels in the culture medium were assayed by a mouse LH-specific RIA, as described
previously, and validated using the LβT2 cell line (24, 28, 29). The intra- and interassay coefficients of
variance were <10% for LH RIA. For the SN assay, 1 million LβT2 cells were treated with 10 nM
mGnRH-A for 6 and 12 h, and the culture medium was lyophilized and resuspended in 150 μl of RIA
buffer. The SN RIA was performed as described (12). The RIA detects SN (SgII 154–186) and any larger
protein derived proteolytically from SgII containing the SN sequence. The linear range of the RIA was
2–60 fmol. Expectedly, gel filtration analysis (16) of 60 fractions of LβT2 cell culture medium indicated
that ∼52 and 27% of the total SN IR was SN and the SgII precursor, respectively (data not shown).
After a 6-h static incubation with
mGnRH-A and SN, the LβT2 cells were carefully washed with 1× PBS. Total RNA was isolated using the
RNeasy Micro Kit (Qiagen, Hilden, Germany), following the company's standard protocol. cDNA
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synthesis and real time RT-PCR methods and validation steps were described previously by our
laboratory (23). Briefly, after RNA levels were measured using the NanoDrop ND-100
Spectrophotometer (Thermo Scientific, Wilmington, DE), aliquots of 2 μg of DNA-free RNA were used to
synthesize cDNA with 200 ng of random primers (Invitrogen, Carlsbad, CA) and Superscript II RNase
H  reverse transcriptase (Invitrogen). The PCR primers were designed using Primer 3
(http://frodo.wi.mit.edu), verified by IDT OligoAnalyzer 3.1
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer), and synthesized by Invitrogen. Based
on the published mouse sequences, the primer sets in the present investigation are LHβ (NM_008497:
forward 5′-CTGTCAACGCAACTCTGG-3′, reverse 5′-AGGGCTACAGGAAAGGAG-3′), SgII
(NM_009129: forward 5′-CTACCCTGGAGTCTGTGTTC-3′, reverse 5′-TTGCTGTCTCTCACCTCTTC-
3′), CgA (NM_007693: forward 5′-AGCATCCAGTTCCCACTT-3′, reverse 5′-
AAGCCTCTGTCTTTCCATC-3′), and 18S ribosomal RNA (X00686: forward 5′-
GATACCGTCGTAGTTCC-3′, reverse 5′-ATCTGTCAATCCTGTCC-3′) as a control for RNA loading.
Depending on the sequence, amplification of cDNAs was performed with 150–300 nM of primers using
the Mx3000 Mulitplex Quantitative PCR System (Stratagene, La Jolla, CA).
The LβT2 cells were removed from the six-well
culture plates and collected by centrifuging at 2,000 rpm for 10 min. After these cells were sonicated in a
homogenizing buffer, a protein extract was obtained from the supernatant and analyzed by Western
blots, as described previously (47). Our anti-goldfish SN antiserum (dilution: 1:2,000–1:4,000) was
generated against the 15-amino acid antigenic peptide YTPQKLATLQSVFEE, which is the most
conserved central core of the SN sequence between various vertebrate species (46). The antibody
specifically recognizes SN in fish and mammals, including human (46, 48). The anti-actin antibody
(A2066, dilution: 1:500; Sigma, St. Louis, MO), phospho p44/42 MAP kinase (ERK1/2; Thr /Tyr )
antibody (9101S, dilution: 1:600–1:1,000; Cell Signaling Technology), and p44/42 MAPK (ERK1/2)
rabbit antibody (9102, dilution: 1:1,000; Cell Signaling Technology) were purchased from the indicated
suppliers. Both MAPK antibodies were previously validated for use on LβT2 cells (20).
The LβT2 cells was preincubated with serum-free DMEM for 15 min and
then changed to DMEM with 100 nM mGnRH-A and/or 100 nM SN and incubated for 0.5 h. The
intracellular and extracellular cAMP level was determined as described previously (10, 17, 36). Total
cAMP level is the sum of the intracellular and extracellular cAMP levels.
Human embryonic kidney (HEK)-293 cells transfected with a GnRH
receptor (GnRHR) reporter construct were used to test the possibility that SN could activate the GnRHR.
The experimental protocol was described in detail previously by Oh et al. (30). The cellular transfection
was performed using the SuperFect transfection kit (Qiagen, Chatsworth, CA), 100 ng of rat GnRHR
cDNA that was constructed at EcoRI and XbaI sites of pcDNA3 (Invitrogen, San Diego, CA), and 200 ng
of SRE-luc (luciferase) vector [containing a single copy of the serum response element (SRE)
CCATATTAGG followed by c-fos basic promoter] along with 200 ng of the internal control plasmid
pCMV-Gal. The cells were treated with natural mGnRH and/or rat SN (Anygen, Gwangju, South Korea)
for 6 h, and then the luciferase activity in the cell extract was determined.
Data were expressed as means ± SE. The statistical analyses were carried out using Sigma
Stat version 3.5. The effects of SN and mGnRH-A on LH release and mRNA levels of LHβ, FSHβ, SgII,
and CgA were analyzed using one-way analysis of variance (ANOVA) followed by the Fisher least
significant difference (LSD) test. When the values were nonparametric, data were naturally log-
transformed before one-way ANOVA. When examining the effect of 10 nM mGnRH-A on SgII
processing and SN IR protein release, we utilized either the t-test (for parametric data) or the Mann-
Whitney rank sum test (for nonparametric data) to compare control and mGnRH-A-treated groups. The
phospho-ERK1/2 and total ERK1/2 data were normalized by the average signal intensity for each
membrane. The ratios between normalized phospho-ERK1/2 and total ERK1/2 levels were examined by
one-way or two-way ANOVA followed by Fisher LSD test to determine specific differences among
treatments. If the data were nonparametric, the Kruskal-Wallis one-way ANOVA on ranks was used.
Means were considered significantly different if P < 0.05. Results are presented as means ± SE. The fold
change represents the ratio of the means of two groups of data (i.e., treatment over control/basal).
−
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Effects of 6- and 12-h mGnRH-A treatments on SgII-immunoreactive products in mouse LβT2 pituitary cells.
RESULTS
Various concentrations (1, 10, and 100
nM) of SN were chosen for the time course and dose response study of LH secretion from LβT2 cells. The
levels of LH release to the culture medium increased from 3 to 12 h in the control group as well as in the
mGnRH-A and SN treatments. We adopted 10 nM of mGnRH-A as the positive control in this
experiment (28). After 3 h of treatment, mGnRH-A induced a 3.1-fold increment of LH levels (P <
0.001) compared with the control (Fig. 1). The LH levels after the exposure to 1 and 10 nM SN were 2.9-
(P < 0.001) and 2.6-fold (P < 0.01) higher, respectively, than the time-matched controls. After 3 h, the
LH level in the 100 nM SN group was increased 1.6-fold, but this did not reach statistical significance (P
> 0.05). After a 6-h incubation, LH increased 3.4-fold (P < 0.001) in response to mGnRH-A; exposures
to all SN doses (1–100 nM) enhanced (P < 0.05) LH levels in culture medium 2.9- to 2.7-fold (Fig. 1). In
contrast, the effects of mGnRH-A and SN were no longer evident after 12 h (Fig. 1).
Another experiment was carried out to explore the effects of
SN on LHβ-subunit mRNA levels. Cellular 18S ribosomal RNA levels were not significantly modified
under any treatment (data not shown), and thus it was chosen as an internal standard to normalize the
expression of LHβ-subunit and other genes. In the dose response study (Fig. 1), there was no significant
difference between 1- and 10-nm SN effects on stimulating LH release after either 3 or 6 h. Previous
studies using goldfish pituitary cells in vitro (45, 49) indicated that 10 nM goldfish SN consistently
enhanced LH production, so we examined a similar dose range (1, 10, 100 nM) of mouse SN to
investigate SN-induced LHβ gene expression in LβT2 cells. In the presence of 10 nM mGnRH-A, the LHβ
mRNA level was increased twofold (P < 0.001) compared with the control. This result was consistent
with previous findings using LβT2 cells (38). Treatments of 1–100 nM SN induced 1.8- to 1.6-fold (P <
0.05) increments in LHβ gene expression (Fig. 2A). Furthermore, SN-induced LHβ mRNA levels
exhibited a pattern similar to that of LH secretion after 6 h, which is shown in Fig. 1. Mammalian
GnRH-A-induced LHβ mRNA in cells and LH levels in the culture medium were similar to the effect of
SN. Treatment with mGnRH-A also upregulated SgII mRNA levels 2.4-fold (P < 0.001) compared with
the control. In contrast, SgII mRNA was not affected by any dose of SN during the 6-h static incubation
of LβT2 cells (Fig. 2B). Compared with SgII expression, CgA mRNA levels were not affected by mGnRH-
A and were somewhat reduced by 1 (57%, P < 0.001) and 10 nM (71%, P < 0.05) SN in the 6-h-treated
cells (Fig. 2C).
Our anti-goldfish SN antiserum was
generated against the 15-amino acid antigenic peptide YTPQKLATLQSVFEE, which is the most
conserved part of the SN sequence between various vertebrate species (46). The antigenic peptide shows
80% identity to the middle portion of mSN (48), indicating the possibility of using the anti-goldfish
antibody to examine the SN IR in mice. In addition, our anti-goldfish SN antibody was also used to
detect the SN-IR signals within the pituitary cells in human, rat, and trout (48, 49). To evaluate the
specific binding ability of anti-goldfish SN antibody to the protein extracted from mouse LβT2 pituitary
cells, we carried out Western blot analysis using anti-goldfish SN antiserum preabsorbed with its
antigenic peptide goldfish SN (Fig. 3). We detected several SN-immunoreactive protein bands when using
the anti-goldfish SN antiserum (Fig. 3A, lane I), whereas no signal was observed in the membrane that
was incubated in the SN antibody preabsorbed with SN (Fig. 3A, lane II). These results confirmed that
the SN antiserum recognized SN-associated proteins derived from mouse pituitary cells.
Under a longer enhanced chemiluminescence exposure time than that of Fig. 3A, two strong high-
molecular-weight (MW) bands and two weak low-MW signals were observed in different samples (
Fig. 3B). A standard formula (y = 116.65x , r  = 0.999) was established for describing the
relationship between apparent MW (y) and gel running distance (x) based on protein standards. The
estimated MWs of the two strong and two weak bands were ∼71, ∼46, ∼42, and ∼32 kDa (Fig. 3B). The
∼71-kDa band is corresponding to the size of the unprocessed mouse SgII precursor. The mouse SgII
sequence is 617 amino acids with a calculated MW of 70.6 kDa. Expectedly, the other SN-
immunoreactive signals were noticeably smaller than the calculated MW of the SgII precursor,
indicating that they are processing products derived from this granin.
We
focused on GnRH regulation of SgII products. After a 6-h static incubation, 10 nM mGnRH-A
−0.7 37 8 2
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SN activates the PKC-MAPK cascade in LβT2 cells.
SN regulates the cAMP levels of LβT2 cells.
SN is not able to activate the GnRHR.
significantly decreased the cellular levels of SgII, ∼46-kDa, and ∼32-kDa SN-immunoreactive
polypeptides by 49 (P = 0.05), 28 (P < 0.001), and 37% (P = 0.05), respectively, and also induced a 36%
but statistically nonsignificant decrease (P = 0.505) in the level of ∼42-kDa, SN-immunoreactive, SgII-
derived peptide (Fig. 4, A and B). Twelve-hour treatment of mGnRH-A (10 nM) also modulated the
levels of all SN-immunoreactive peptides. The mGnRH-A treatment decreased the ∼71-, ∼46-, ∼42-,
and ∼32-kDa SN-containing proteins by 63 (P < 0.01), 31 (P < 0.001), 41 (P < 0.05), and 49% (P =
0.05), respectively (Fig. 4, C and D). Note that β-actin served as the protein-loading control and did not
change with treatments (Fig. 4, B and D). Furthermore, 10 nM mGnRH-A increased
radioimmunoassayable SN IR in the culture medium level 3.0- (P < 0.05) and 2.3-fold (P < 0.001) after
6 and 12 h, respectively (Fig. 5, A and B).
ERK is a classic MAP kinase involved in GnRH-
stimulated LH production and release in LβT2 cells (32). In this experiment, Western blot analysis was
used to detect the changes of active phospho-ERK1/2 and total inactive ERK1/2 levels under various
treatments. At first, we examined the acute effect of SN on the activation of ERK1/2. Serum-starved
LβT2 cells were treated with 100 nM mGnRH-A 10 and 100 nM SN for 10 min. As a positive control
group, the treatment of 100 nM mGnRH-A increased activated ERK1/2 3.0-fold (P < 0.001; Fig. 6A),
which is consistent with the data described previously by others (19). Similar to the action of mGnRH-A,
10 and 100 nM SN were capable of inducing 2.2- (P < 0.01) and 4.6-fold (P < 0.001) rapid increments,
respectively, of phospho-ERK1/2 levels (Fig. 6A). The 100-nM SN-stimulated phospho-ERK1/2
increment was significantly higher than that of 100 nM mGnRH-A by 1.6-fold (P = 0.001; Fig. 6A).
When LβT2 cells were exposed to the low-dose treatment for a longer time (3 h), 10 nM SN also
significantly increased the phospho-ERK1/2 levels 1.4-fold (P < 0.05; Fig. 6B). To further define the
signaling pathways involved in activation of ERK by SN, the cells were pretreated with PD-98059 and
BIM-1 to inhibit MEK and PKC, respectively, two major kinases upstream of ERK. We compared the
relative change of activated ERK1/2 after the 10-min stimulation with 100 nM SN and 100 nM
mGnRH-A. PD-98059 significantly reduced both the mGnRH-A- and SN-induced activation of ERK1/2
by 48 (P < 0.05) and 40% (P < 0.01), respectively (Fig. 6C). BIM-1 also significantly (P < 0.001) reduced
both the mGnRH-A- and SN-induced activation of ERK1/2 by 96 and 76%, respectively (Fig. 7A).
After 0.5-h static treatments of mGnRH-A (100 nM) and SN
(100 nM), the total cAMP levels were measured for LβT2 cells. As depicted in Fig. 7B, both mGnRH-A
and SN significantly increased the total cAMP levels 1.4- (P < 0.05) and 1.3-fold (P < 0.05).
In HEK-293 cells transfected with the rat GnRHR, natural mGnRH
significantly increased SRE-luc activity over the range of 1–1,000 nM (Fig. 8), confirming previous data
using the same reporter system (30). However, rat SN (1–1,000 nM) did not affect SRE-luc activity (
Fig. 8A). Moreover, there were no interactions between mGnRH and SN; treatment with 10 μM SN did
not alter (P > 0.05) the SRE-luc response to 100 nM mGnRH (Fig. 8B).
DISCUSSION
Our previous studies in the goldfish model demonstrated that SN has neuroendocrine and paracrine
effects to stimulate LH secretion and production in dispersed pituitary cells (47, 50). We have suggested
that the elevation of intracellular Ca  level is a potential transduction signal mediating SN action on
goldfish LH cells. This SN-induced Ca  signaling mechanism was also demonstrated to be partly
independent of GnRH-stimulated Ca  entry (47). However, the SN signaling pathway in gonadotrophs
is still unclear. Therefore, we chose to study SN action on the LβT2 cell. They have many of the common
characteristics of normal mouse pituitary cells, and the signaling pathways to mediate GnRH-stimulated
LH release are well studied (32). In agreement with our previous research in goldfish (47), the present
study revealed that SN increased not only LH secretion but also the mRNA levels of the LHβ-subunit in
mouse LβT2 cells. Therefore, the effect of SN on LH appears to be evolutionarily conserved and indicates
for the first time a potential regulatory role for SN in mammalian reproduction.
Various studies in the goldfish have shown that SN induces LH release and LHβ-subunit gene expression
in pituitary cells (4, 45, 47). However, studies concerning the regulatory effects of SN in mammalian
neuroendocrine and central nervous systems are quite limited. Secretoneurin was demonstrated to dose-
dependently increase dopamine outflow from superfused rat striatal slices (34). An in vivo experiment
2+
2+
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showed that local infusion of SN into the substantia nigra and neostriatum of halothane-anesthesized
rats elevated the extracellular concentrations of dopamine, γ-aminobutyric acid, and glutamate (44).
Here, we adopted mouse LβT2 gonadotrophs to study the effects of SN on LH release. In this cell line,
there is a close correlation between GnRH-induced LH release and secreted SN-immunoreactive SgII-
like proteins. A possible regulatory effect of SgII (or derived peptides) on LH secretion from LβT2
gonadotrophs had been proposed previously (28). We found that the effective concentrations of SN to
stimulate LH release in vitro from both LβT2 gonadotrophs and goldfish pituitary fragments are similar
(45). A similar dose range and effect of SN were also observed in primary cultures of dispersed goldfish
pituitary cells. Six-hour static treatment of 10 nM SN significantly increased LH secretion from
gonadotrophs (47). We conclude that low physiologically relevant nM doses of SN are able to stimulate
LH secretion from pituitary cells.
During the 3- and 6-h static cultures, the LβT2 cells were very sensitive to even the lowest dose of SN (1
nM) tested. Similar to the effect of SN in LβT2 cells, a low-dose pulse of 10 nM GnRH could induce more
LH release than 50 and 200 nM GnRH in the same cell line (28). Unlike LβT2 gonadotrophs, which are
tumor derived, dispersed normal mouse pituitary cells show a classical LH response to increasing doses of
GnRH after 4-h static treatments over a wide range of GnRH concentrations (10–1,000 nM) (1). This
difference between LβT2 gonadotrophs and normal pituitary cells is likely due to alteration of secretory
pathways, a well-known characteristic of the highly selected LβT2 cell line. A previous investigation
revealed that 10 and 100 nM GnRH evoked a similar increment in exocytosis as well as intracellular
Ca  level within a single LβT2 cell (37). These authors' interpretation of the result was that only ∼400
vesicles were found to be involved in fusion with the plasma membrane for further secretion. Thus,
secretion under the long-term stimulation of the LβT2 cell might be highly limited by the availability of
secretory products (37). The secretory limitation was also observed in long-term GnRH-evoked LH
release; the LH secretory response declined dramatically under the repeated stimulation of GnRH for
several hours in LβT2 cells (38). In contrast, multiple administrations of GnRH to perifused normal rat
pituitary cells always induced dose-dependent LH release (21). It is likely that the absence of a dose
response to SN-induced LH release over the dose range tested results from this limitation of secretory
vesicles in the mouse LβT2 cell line. Nevertheless, we show for the first time that SN stimulates LH
release from mouse pituitary cells in a manner similar to that which we have documented for normal
goldfish pituitary cells in vitro.
To further examine the effects of SN on LH generation, we demonstrated that the increasing doses of SN
induced similar increment in LHβ gene expression within LβT2 gonadotrophs, consistent with the pattern
of SN-induced LH release. An unvaried LH synthesis under increasing doses of SN treatments might be
an alternative explanation for the absence of a dose-dependent effect of SN on LH secretion in LβT2 cells.
Interestingly, the levels of SN-induced LH release (2.6- to 2.8-fold increase) were higher than those of
LHβ-subunit mRNA (1.6- to 1.8-fold increment). SN might affect not only LHβ mRNA synthesis but also
other pathways associated with LH protein generation and secretion. This possibility has been suggested
but never tested in a previous study using this cell line (28). The acute GnRH-induced LH protein
synthesis and secretion were dependent mainly upon the activation of translation initiation proteins 4E-
binding protein 1 and eukaryotic initiation factors 4E/4G but not LHβ transcription. The stimulation of
these proteins by GnRH was mediated by the MAPK/ERK pathways (27). The stimulatory effects of SN
on the MAPK cascade in the LβT2 cell line (this study) indicate the possibility of multiple pathways
mediating SN-induced LH release.
In comparison with pulsatile GnRH stimulation that increased the secretion of both SgII and CgA from
perifused LβT2 cells (28), we determined that static exposure to mGnRH-A also increased the cellular
level of SgII mRNA but had no remarkable effect on CgA gene expression. However, Nicol et al. (28)
reported that the pulses of GnRH did not alter SgII mRNA level in estradiol- and dexamethasone-treated
LβT2 cells. The variation between our data and early observations might be attributed to differences in
GnRH stimulation strategies and the different in vitro models adopted. Under the same conditions as the
GnRH treatment, SN was unable to elicit any changes in SgII mRNA levels in our experiment with LβT2
cells. In contrast, SN significantly decreased CgA mRNA levels at the doses of 1 and 10 nM. These data
indicate that, under the in vitro conditions described, mGnRH-A and SN are acting differentially on
expression of SgII and CgA. They are both granins but from distinctly different molecular families (48).
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Our previous studies of SN generation in goldfish revealed the formation of several SgII-derived proteins
and polypeptides. In the pituitary, we detected proteins of molecular masses of ∼57, ∼30, ∼19.6, ∼15,
and ∼12 kDa in addition to the free SN peptide (molecular mass: 3,655 Da) (46, 47). Using a similar
strategy, we discovered four SN-immunoreactive signals with distinct molecular masses predicted as
∼71, ∼46, ∼42, and ∼32 kDa in mouse LβT2 gonadotrophs. Moreover, the ∼71- and ∼46-kDa proteins
showed significantly higher levels than the ∼42- and ∼32-kDa polypeptides. Some of the resultant
processing products have sizes similar to those reported for other mammalian SgIIs (9, 11, 39). Almost
all of the SgII precursor protein is processed to generate free SN in normal rat pituitary (18), and
gonadotrophs secrete SN-immunoreactive products (Ref. 28 and this study).
It was demonstrated previously using RIA that GnRH decreased the cell content and increased the
secretion of total SgII-related proteins from LβT2 cells (28). Under the conditions of in vitro culture, the
speed of GnRH-induced SgII processing appears to be faster than SgII generation at some time points,
which explains the observed decrease in cellular SgII-related proteins (28). Consistent with this, our
Western blot analysis showed that GnRH was able to decrease cellular levels of SgII and its derived
proteins. Moreover, GnRH also increased SN-immunoreactive protein release from mouse LβT2 pituitary
cells and GnRH-increased SgII mRNA levels, indicating the potential for increased SgII precursor
protein production. This result is similar to what we found in goldfish in vivo (33) and in vitro (50).
These data indicate that GnRH enhances SgII synthesis and processing.
The MAPK cascade is one of the essential GnRH-activated G protein-coupled signaling pathways to
induce early genes for gonadotropin production and release. The MAPK pathway includes mainly ERK,
p38 MAPK, and c-Jun NH -terminal kinase (JNK) (32). The activated form of ERK is phosphorylated on
threonine and tyrosine residues within the phosphorylation lip (5). In the LβT2 cell line, GnRH was
demonstrated to rapidly activate ERK and p38 MAPK, but activation of JNK was weaker and slower (19).
In agreement with this previous report, our observations confirmed that the 10-min acute mGnRH-A
treatment caused the activation of ERK in LβT2 cells. Similarly to the stimulatory action of mGnRH-A,
10 and 100 nM SN also increase the ERK phosphorylation 2.2- and 4.6-fold, respectively. However,
chronic GnRH exposure can suppress PKC- and cAMP-induced ERK activation in LβT2 cells (20). In
another experiment, we found that long (3 h) exposure to a low dose (10 nM) of SN treatment still
stimulated ERK phosphorylation, but this was weaker than that observed at 10 min. MEK, in association
with GnRH-stimulated PKC and Raf, has been reported to stimulate activation of downstream ERK in
LβT2 cells (19). We also found that the inhibition of MEK with PD-98059 reduced both GnRH-A and SN-
induced ERK phosphorylation. This result indicates that SN signals through the ERK-dependent MAPK
pathway.
PKC is the most important signaling molecule to connect the G protein-coupled signal transduction and
the MAPK cascade for mediating GnRH-induced LH subunit gene transcription (25). Activation of ERK
caused by GnRH-induced PKC was reported for rat pituitary cells (42) and the mouse αT3–1
gonadotropin cell line (35). Liu et al. (19) demonstrated that GnRH activated ERK and two other MAPK
family members, JNK and p38 MAPK, via a PKC-dependent signaling pathway in LβT2 cells. We
observed that SN-induced ERK activation was significantly blocked by pharmacological inhibitors of PKC
and MEK. SN-regulated migration and number of mouse endothelial progenitor cells in the
inflammatory system are also via ERK activation (15). A previous study also showed that cAMP is
involved in activating ERK to mediate GnRH-induced LH generation in LβT2 cells (20). Moreover, cAMP
is important for GnRH-regulated G protein-coupled PKA signaling transduction in LβT2 cells (32).
Secretoneurin exposure elevated total cAMP production in LβT2 cells, providing additional evidence for a
G protein-coupled signaling pathway. To exclude the possibility that SN binds to the GnRHR to activate
these transduction pathways, we examined GnRHR-induced SRE-luc activities following SN treatments
of transfected HEK-293 cells. In this sensitive system, SN did not activate the rat GnRHR, and SN did not
interfere with GnRH action. These data support the proposal that the putative receptor-linking SN action
to cAMP-dependent and PKC-MAPK signaling pathways and LH synthesis is distinct from the GnRHR.
In conclusion, results from the present study provide the first evidence for a direct stimulatory action of
SN on LH release and LHβ-subunit mRNA levels in mammalian pituitary cells. Furthermore, we have
shown that SN activates ERK, which is likely involved in the stimulation of LHβ-subunit transcription
via multiple G protein-coupled signaling pathways, including the PKC-MAPK and cAMP-dependent
2
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mechanisms, in a similar manner as that observed for GnRH actions on LβT2 cells. GnRH regulates SN-
immunoreactive peptides derived from SgII in the gonadotroph, suggesting that endogenous SN is a
participant in an autocrine mechanism under the control of hypothalamic hormones. The studies of SN
production, biological activities, and functional mechanisms in a mouse gonadotroph cell line support
our hypothesis that SN is an evolutionarily conserved hormonal peptide involved in the regulation of
vertebrate reproduction (45, 47, 50). To our knowledge, the clearest example of an endocrine role for SN
is the stimulatory effects on LH release that we report in both fish and mammalian model systems. We
suggest that SN activates a G protein-coupled receptor in gonadotrophs. Future investigations must focus
on isolating the SN receptor, which has yet to be identified in any species.
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Figures and Tables
Fig. 1.
Time- and dose-dependent effects of secretoneurin (SN; 1 , 10, and 100 nM) and mammalian GnRH agonist
(mGnRH-A; 10 nM) after 3-, 6-, and 12-h static incubation on LH secretion from the mouse LβT2 pituitary  cells.
Results are presented as means ± SE (n = 9–10). One-way  ANOVA was chosen to assess the difference between
control and treatment at a given time point, followed by  Fisher least significant difference (LSD) test. Natural
logarithms were adopted if data were not normally  distributed in statistics. *Significant difference from control at
a given time point (P < 0.05).
Fig. 2.
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Assessment of the gene expression changes of LHβ (A), secretogranin II (SgII; B) and chromogranin A (CgA; C) in
LβT2 cells after 6-h static incubation with treatments of 10 nM mGnRH-A and 10 nM SN. The mRNA level was
measured by  real-time RT-PCR; 18S ribosomal RNA was used as an internal standard for sample loading control.
One-way  ANOVA was chosen to assess the difference between control and treatment, followed by  Fisher LSD test.
Natural logarithms were adopted if data were not normally  distributed in statistics. Values are expressed as mean
folds of control ± SE. *Significant difference relative to control (P < 0.05).
Fig. 3.
Western blotting analy sis of the total proteins exacted from mouse LβT2 cells using anti-SN antibody  (1 :2,000–
1:4,000). A : 30 μg of protein extracts was separated by  10% SDS-PAGE gel and detected by  anti-goldfish SN
antiserum (46). Lane I: detection using anti-SN antibody  (1 :4,000); lane II: detection using anti-SN antibody
(1:4,000) preabsorbed by  1  μM goldfish SN. B: the loading samples of lanes I and II are taken from different
culture wells. Arrows indicate 4 SN-immunoreactive signals that are ∼7 1, ∼46, ∼42, and ∼32 kDa. Their
estimated molecular weights (EMW) are calculated from a standard curve and a formula depicting the relation
between molecular weight of biotiny lated protein standards and gel running distance.
Fig. 4.
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Effects of mGnRH-A (G) on intracellular content of SgII and derived peptides containing the SN sequence in LβT2
cells. A  and B: levels of SN-immunoreactive (IR) proteins (∼7 1, ∼46, ∼42, and ∼32 kDa) were analy zed by
Western blots using anti-SN antibody  (dilution 1 :2,000) after 6-h treatment of 10 nM mGnRH-A. C and D: the
expression changes of SN-IR proteins under 12-h static incubation of mGnRH-A (10 nM). β-Actin was measured
as an internal standard for loading control (C). Note that no signal was observed on membranes that were
incubated in the SN antibody  preabsorbed (4°C for 18 h) with 1  μM SN (not shown), confirming prev iously
reported specificity  (46, 48). For A  and C, results were presented as means ± SE of the relative expression of SN-
IR; n = 8 for both experiments. Western blots of SN and β-actin were preformed on the same membrane. The
results of ∼42- and ∼46-kDa protein intensities and SN-IR protein release after 12-h treatment were parametric,
and the rest of the data were nonparametric. When the data were nonparametric, Mann-Whitney  rank sum test
was used instead. *Significant difference between treatment and control (P < 0.05).
Fig. 5.
Ten nanomolars of mGnRH-A stimulates the release modification of SN-IR protein release into culture medium
after 6 (A) and 12 h (B). Note that Western blots of SN and β-actin were preformed on the same membrane. A t-
test was used to compare control and mGnRH-A groups. *Significant difference between treatment and control (P
< 0.05).
Fig. 6.
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Action of SN to stimulate ERK1/2 in LβT2 cells. A : both mGnRH-A (100 nM) and SN (10 and 100 nM) stimulated
ERK phosphory lation. These cells were cultured in serum-free DMEM overnight and stimulated by  mGnRH-A and
SN for 10 min. Protein extracts were first-analy zed Western blots with the antibody  for phosphory lated ERK1/2
(p-ERK; II, top). After p-ERK1/2 blots were stripped, the membranes were immunoblotted again with the total
ERK1/2 antibody  (II, bottom). In I, data were presented as means ± SE of the normalized ratio between p-
ERK1/2 and total ERK1/2; n = 5. One-way  ANOVA was chosen to assess the difference from control, followed by
Fisher LSD test. *Significant difference between treatment and control (P < 0.01). B: SN (10 nM) activated ERK
after 3 h. Cells were stimulated with a low dose of SN for 3 h in the static incubation. Western blots were used to
assess p-ERK1/2 (II, top) and total ERK (II, bottom). The normalized ratio of 3-h-induced p-ERK/total ERK is
shown as means ± SE in I. *Statistical difference (P < 0.01, t-test; n = 5). C: PD-98059 (20 μM, a MEK inhibitor)
attenuated ERK1/2 phosphory lation. LβT2 cells were cultured in serum-free medium overnight and pretreated
with 0.1% DMSO (the PD-98059 vehicle) and 20 μM PD-98059 for 1  h and then stimulated by  mGnRH-A (100 nM)
and mouse SN (mSN; 100 nM), respectively , for 10 min. Cellular exacts were separated by  10% SDS-PAGE gel and
detected by  p-ERK and ERK1/2 antibodies. In I, relative change of normalized ratio (p-ERK/ERK) with respect to
the group-matched control value was shown as means ± SE (n = 6). *P < 0.05 vs. treatment without the MEK
inhibtor PD-98059. The statistical difference was analy zed by  2-way  ANOVA followed by  Fisher LSD method. In
II, the changes of signal intensities for p-ERK1/2 (top) and total ERK1/2 (bottom) were exhibited. Note that
Western blots of ERK and p-ERK were preformed on the same membrane.
Fig. 7.
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A : bisindoly lmaleimide (BIM-1; a PKC inhibitor) reduced ERK1/2 phosphory lation. LβT2 cells were cultured in
serum-free DMEM overnight and pretreated with 0.1% DMSO (BIM-1  vehicle) and 2 μM BIM-1  for 0.5 h and then
stimulated by  mGnRH-A (100 nM) and SN (100 nM), respectively , for 10 min. Cellular exacts were separated by
10% SDS-PAGE gel and detected by  p-ERK1/2 and ERK1/2 antibodies. In I, relative change of normalized ratio (p-
ERK/ERK) with respect to the group-matched control value was shown as means ± SE (n = 4). Different letters
represent statistical differences (P < 0.001 vs. treatment without BIM-1). The statistical difference was analy zed
by  2-way  ANOVA, followed by  Fisher LSD method. In II, the changes of signal intensities for phospho-ERK1/2
(top) and total ERK1/2 (bottom) were exhibited. B: the effects of SN (100 nM) and mGnRH-A (100 nM) on the
total cAMP levels of LβT2 cells after 0.5 h. Results presented means ± SE; n = 6. One-way  ANOVA was chosen to
assess the difference between basal and treatments. The data were nonparametric and the Student-Newman-
Keuls method was used for analy sis. *Significant difference relative to control (P < 0.05). Note that Western blots
of ERK and p-ERK were preformed on the same membrane.
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Lack of SN activ ity  on rat gonadotropin-releasing hormine receptor (GnRHR). human embry onic kidney -293
cells were transiently  transfected with 100 ng of rat GnRHR and 200 ng serum response element (SRE)-luc
reporter construct. A : the SRE-driven transcriptional activ ity  in response to various concentrations of 1–1,000
nM (10 –10  mol/l) for natural mGnRH and rat SN. *P < 0.001 vs. the basal SRE-luc activ ity  (n = 3). Data were
analy zed by  2-way  ANOVA followed by  Fisher LSD method. B: mGnRH (100 nM)-induced GnRHR activ ity  in the
presence or absence of rat SN (10 μM). Data are shown as means ± SE (n = 3). One-way  ANOVA followed by  Fisher
LSD method was used to assess the difference between basal and treatments. Different letters indicate that
means are significantly  different from each other (P < 0.001).
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